Abstract
Erectile dysfunction (ED) is defined as the consistent inability to achieve or maintain an erection. This may affect around 50% of men between the ages of 40 and 70, while persistent ED affects about 5% of men in their 40s, and 15–25% of men by the age of 65 [1]. As life expectancy increases, the incidence of ED is expected to rise.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 151(1):54–61
Andersson KE (2003) Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 170(2 Pt 2):S6–S13
Chiurlia E, D’Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG (2005) Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 46(8):1503–1506
Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S (2005) Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 47(1):80–85
Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C (2007) Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 52(6):1590–1600
Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A et al (2003) Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44(3):360–364
Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A et al (2006) Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 27(22):2632–2639
Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M et al (2008) British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 5(8):1841–1865
Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S et al (2004) Summary of the recommendations on sexual dysfunctions in men. J Sex Med 1(1):6–23
Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C et al (2005) Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 95(1):110–116
Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, Valiquette L et al (2004) Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 45(3):339–344
Boshier A, Wilton LV, Shakir SA (2004) Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 93(6):796–801
Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A et al (2006) Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 50(1):134–140
Ljunggren C, Hedelin H, Salomonsson K, Stroberg P (2008) Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 5(2):469–475
Stroberg P, Hedelin H, Ljunggren C (2006) Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction – a realistic and feasible option in everyday clinical practice – outcomes of a simple treatment regime. Eur Urol 49(5):900–907
British National Formulary. Publisher Pharmaceutical Press; 56 edition (1 Sep 2008). ISBN-13: 978-0853697787
The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group (1998). Br J Urol: 82(4):538–543
Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves LF et al (2008) Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 5(9):2160–2169
Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G et al (2008) Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 25(2):138–146
Zumbe J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E (2008) Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 54(1):204–210
Solomon H, Man JW, Jackson G (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89(3):251–253
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London
About this chapter
Cite this chapter
Li, CY., Ralph, D. (2010). Erectile Dysfunction. In: Shergill, I., Arya, M., Grange, P., Mundy, A. (eds) Medical Therapy in Urology. Springer, London. https://doi.org/10.1007/978-1-84882-704-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-84882-704-2_12
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-703-5
Online ISBN: 978-1-84882-704-2
eBook Packages: MedicineMedicine (R0)